منابع مشابه
Recombinant follitropin alfa/lutropin alfa in fertility treatment
Recombinant human follicle stimulating hormone (rFSH) and luteinizing hormone (LH), also known as follitropin alpha and lutropin alpha, are manufactured by genetic engineering techniques which ensure high quality and batch to batch consistency. Follitropin alpha can be used for controlled ovarian hyperstimulation in assisted reproduction, ovulation induction for WHO group I and II anovulatory i...
متن کامل(alfa-as submitted TC)
A c l a s s o f c o u n t a n d t h r e s h o l d m e c h a n i s m s , c o l l e c t i v e l y d u b b e d α c o u n t , a b l e t o d i s c r i m i n a t e b e t w e e n t r a n s i e n t f a u l t s a n d i n t e r m i t t e n t f a u l t s i n c o m p u t i n g s y s t e m s i s p r e s e n t e d . T r a n s i e n t f a u l t s d i s c r i m i n a t i o n h a s l o n g b e e n p u r s u e d...
متن کاملALFA Fine Grain Data
This paper presents a new version of ALFA VER92], a ne grain dataaow machine. This machine uses the static dataaow execution model and is constituted by 128 clusters; each cluster groups 128 identical Functional Units (FU) with homogeneous I/O conditions. The peculiarity of this machine is the possibility to map directly part of dataaow graph programs in hardware for the simple FU design VER94b...
متن کاملPharmacology of darbepoetin alfa.
The distinct molecular structure of darbepoetin alfa, in both its amino acid sequence and its carbohydrate content, results in a biologic profile with lower binding affinity, longer circulating half-life, and higher in vivo potency compared with the epoetins. The mechanisms responsible for these differences in biological effects have not been fully explained. Pharmacokinetic investigations of d...
متن کاملDarbepoetin alfa (Aranesp).
BUMC PROCEEDINGS 2002;15:332–335 The Food and Drug Administration (FDA) approved darbepoetin alfa (Aranesp) for treatment of anemia as sociated with chronic renal failure (CRF) in patients on dialysis and patients not on dialysis (1). The manufacturer of the drug also filed an application with the FDA on September 18, 2001, to receive an indication for treatment of anemia in patients with cance...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Revista Brasileira de Hematologia e Hemoterapia
سال: 2006
ISSN: 1516-8484
DOI: 10.1590/s1516-84842006000200005